Johnson & Johnson halted a big trial of its experimental HIV vaccine in the Americas and Europe, a disappointment for hopes of battling the global infectious disease after a similar form of the shot failed earlier in a study in Africa.
The Mosaico study ended early after an independent data and safety monitoring board found it didn’t significantly reduce the risk of HIV infection, the company said Wednesday in a statement. The study had been testing the vaccine, which exposes the immune system to HIV proteins via another harmless virus called adenovirus26, in 3,900 people.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.